Castle Biosciences (NASDAQ:CSTL – Get Free Report) and Gaxos.ai (NASDAQ:GXAI – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.
Earnings & Valuation
This table compares Castle Biosciences and Gaxos.ai”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Castle Biosciences | $344.23 million | 2.70 | -$24.16 million | ($0.66) | -46.17 |
| Gaxos.ai | $1.93 million | 3.14 | -$3.90 million | ($0.63) | -1.35 |
Analyst Ratings
This is a breakdown of current recommendations for Castle Biosciences and Gaxos.ai, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Castle Biosciences | 1 | 1 | 7 | 1 | 2.80 |
| Gaxos.ai | 1 | 0 | 0 | 0 | 1.00 |
Castle Biosciences currently has a consensus target price of $42.00, indicating a potential upside of 37.84%. Given Castle Biosciences’ stronger consensus rating and higher probable upside, research analysts plainly believe Castle Biosciences is more favorable than Gaxos.ai.
Insider and Institutional Ownership
92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 42.6% of Gaxos.ai shares are held by institutional investors. 6.1% of Castle Biosciences shares are held by insiders. Comparatively, 3.2% of Gaxos.ai shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Castle Biosciences has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Gaxos.ai has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.
Profitability
This table compares Castle Biosciences and Gaxos.ai’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Castle Biosciences | -5.43% | -4.15% | -3.45% |
| Gaxos.ai | -131.28% | -34.42% | -33.12% |
Summary
Castle Biosciences beats Gaxos.ai on 11 of the 15 factors compared between the two stocks.
About Castle Biosciences
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
About Gaxos.ai
Gaxos.ai Inc. engages in developing artificial intelligence applications for various sectors. Its portfolio includes applications in mental and physical wellbeing, coaching, and gaming. In addition, it offers Gaxos, a gaming platform develop, design, acquire, and manage conventional games and combine these games with unconventional game mechanisms. The company was formerly known as The NFT Gaming Company, Inc. and changed its name to Gaxos.ai Inc. in January 2024. Gaxos.ai Inc. was incorporated in 2021 and is based in Roseland, New Jersey.
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
